Rudkin Brian B.
Brian B. Rudkin / DR2 - CNRS
Research interests
Research Director at the CNRS within the Stem Cell and Brain Research Institute (SBRI), Inserm U1208, University of Lyon and Co-Founder, in 2009, of the Joint Laboratory on Neuropathogenesis along with Prof. Chonggang YUAN at East China Normal University (ECNU) in Shanghai, integrated into the Key Laboratory of Brain Functional Genomics at the ECNU in January 2014.
The main objective is the transfer of fundamental discoveries using small antibody mimetics called peptide aptamers, to potential patient benefit in the context of the StemGamE platform.
The present transfer focus: • neurodegenerative diseases - e.g. ALS (Amyotrophic Lateral Sclerosis - Maladie de Charcot) • stimulation of the immune response e.g. for adoptive cell therapy of certain cancers • enhancement of safety of the use of embryonic stem cell-derived cultures for potential therapeutic benefit.
Member of Platforms
Selected Publications of Brian B. Rudkin
| Year | Reference | Title | Authors |
Journal |
PUB MED | ||
|---|---|---|---|---|---|---|---|
| 1989 | 24(1):49-58 | Differentiation of PC12 cells with v-src: comparison with nerve growth factor | Rausch DM, Dickens G, Doll S, Fujita K, Koizumi S, Rudkin BB, Tocco M, Eiden LE, Guroff G | J Neurosci Res | - | ||
| 1999 | 73(10):8762-70 | Possible interactions between the NS-1 protein and tumor necrosis factor alpha pathways in erythroid cell apoptosis induced by human parvovirus B19 | Sol N, Le Junter J, Vassias I, Freyssinier JM, Thomas A, Prigent AF, Rudkin BB, Fichelson S, Morinet F | J Virol | - | ||
| 1988 | pp. 273-277, Alan R. Liss, Inc | Correlation between the substrate specificity of a Hela mismatch binding protein and the efficiency of mismatch repair in vivo | Jiricny, J, Rudkin BB, Brown TC, Corman N | Mechanisms and Consequences of DNA Damage Processing | - | ||
| 2009 | 535:373-88 | Peptide aptamers for small molecule drug discovery | Bardou C, Borie C, Bickle M, Rudkin BB, Colas P | Methods Mol Biol | - | ||
| 2007 | 18(12):4899-910 | CD44 and beta3 integrin organize two functionally distinct actin-based domains in osteoclasts | Chabadel A, Bañon-Rodríguez I, Cluet D, Rudkin BB, Wehrle-Haller B, Genot E, Jurdic P, Anton IM, Saltel F | Mol Biol Cell | - | ||
| 2005 | 25(12):5106-18 | Critical role for Kalirin in nerve growth factor signaling through TrkA | Chakrabarti K, Lin R, Schiller NI, Wang Y, Koubi D, Fan YX, Rudkin BB, Johnson GR, Schiller MR | Mol Cell Biol | - | ||
| 2013 | 12(7):1939-52 | Calcineurin A versus NS5A-TP2/HD domain containing 2: a case study of site-directed low-frequency random mutagenesis for dissecting target specificity of peptide aptamers | Dibenedetto S, Cluet D, Stebe PN, Baumle V, Léault J, Terreux R, Bickle M, Chassey BD, Mikaelian I, Colas P, Spichty M, Zoli M, Rudkin BB | Mol Cell Proteomics | - | ||
| 2007 | 6(12):2110-21 | A comparative analysis of perturbations caused by a gene knock-out, a dominant negative allele, and a set of peptide aptamers | Abed N, Bickle M, Mari B, Schapira M, Sanjuan-España R, Robbe Sermesant K, Moncorgé O, Mouradian-Garcia S, Barbry P, Rudkin BB, Fauvarque MO, Michaud-Soret I, Colas P | Mol Cell Proteomics | - | ||
| 2007 | 6(11):1842-54 | Nerve growth factor receptor TrkA signaling in breast cancer cells involves Ku70 to prevent apoptosis | Com E, Lagadec C, Page A, El Yazidi-Belkoura I, Slomianny C, Spencer A, Hammache D, Rudkin BB, Hondermarck H | Mol Cell Proteomics | - | ||
| 2007 | 6(3):451-9 | An antiproliferative genetic screening identifies a peptide aptamer that targets calcineurin and up-regulates its activity | de Chassey B, Mikaelian I, Mathieu AL, Bickle M, Olivier D, Nègre D, Cosset FL, Rudkin BB, Colas P | Mol Cell Proteomics | - | ||